January 2018January 2018
New Product - Praluent
Praluent (alirocumab (rch)) is a fully human monoclonal antibody that binds with high affinity and specificity to PCSK9. PCSK9 binds to the low density lipoprotein (LDL) receptors (LDLR) on the surface of hepatocytes to promote their degradation. By inhibiting the binding of PCSK9 to LDLR, alirocumab increases the number of LDLR available to clear LDL, thereby lowering LDL cholesterol (LDL-C) levels. Praluent is indicated as an adjunct to diet and exercise to reduce LDL-C in adults with one or more of: heterozygous familial hypercholesterolaemia, clinical atherosclerotic cardiovascular disease, or hypercholesterolemia with high or very high cardiovascular risk. In combination with a statin, or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with maximum tolerated dose of a statin; or in combination with other lipid lowering therapies in patients who are statin intolerant or for whom a statin is contraindicated who are unable to reach LDL-C goals. The effect of Praluent on cardiovascular morbidity and mortality has not yet been determined. Praluent is contraindicated with hypersensitivity to the active substance or to any of the excipients. For contraindications related to concomitant statins or other lipid modifying therapy, refer to their current respective product information. Praluent solution for injection is supplied in a 75 mg/mL and 150 mg/mL prefilled pen, available in pack sizes of 1, 2 or 6 per carton.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au